
Principle and meant use
Immupass VivaDiag SARS-CoV-2 Ag Quick Examine is supposed for medical laboratories and healthcare expert use only for point-of-care testing. Not for at-home testing.
Immupass VivaDiag™ SARS-CoV-2 Ag Quick Examine depends on immunoassay know-how. Each test system has one line of anti-SARS coronavirus monoclonal antibody on the detection line (T line) and one line of anti-mouse IgG polyclonal antibody on the usual administration line (C line).
When extracted specimen is added to the specimen correctly, it ought to react with the labeled antibody to kind a fancy, the mix then migrates by means of the membrane by capillary movement and interacts with the coated anti-SARS coronavirus monoclonal antibody on the detection line. If the specimen contains SARS-CoV-2 antigen, the detection line will appear purplish-red indicating the SARS-CoV-2 antigen is optimistic.
In some other case, the test finish end result shall be detrimental. The test system moreover contains a high quality administration line C which ought to appear purplish-red for all official assessments. If the usual administration line C does not appear, the test finish end result shall be invalid even when the detection line appears.
VivaDiag SARS-CoV-2 Ag Quick Examine depends on immunoassay know-how for the speedy, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human oropharyngeal or nasopharyngeal swab specimens. The test generates a finish end result inside 15 minutes determining people contaminated with COVID-19 quickly serving to to comprise the unfold of the virus.
The bundle contains all devices required along with swab, extraction tube, extraction decision and lateral circulation test system. No specialised gear or personnel is required to utilize this test. The assessments could also be carried out in any setting at any time by educated personnel, i.e for expert use solely
This lateral circulation Covid-19 Quick Antigen Examine Tools is for simple for educated personnel to handle delivering right outcomes rapidly using the oropharyngeal or nasopharyngeal swab specimen.
With the specimen collected insert the swab into the extraction tube full of extraction decision. Having eradicated a testing system from the sealed pouch apply three drops of the reply and wait 15 minutes sooner than learning the test, a optimistic or detrimental end result’s clearly indicated.

This Covid-19 Quick Antigen Examine Tools has an basic accuracy of 98.79%, a specificity of 99.12% and a sensitivity of 90.90% providing full assurance of fast, right, reliable outcomes.
These assessments should be used as part of a completely built-in COVID-19 approach, serving to find out these contaminated to chop again the unfold of the virus. VivaDiag™ SARS-CoV-2 Ag Quick Examine has ONLY been designed to behave as a supplementary test for suspected situations of detrimental coronavirus nucleic acid detection or together with nucleic acid detection throughout the evaluation of suspected situations. Outcomes from nucleocapsid protein antigen testing should not be used as the one actual basis to diagnose or exclude SARS-CoV-2 (COVID-19) an an infection or to inform an an infection standing.
Composition
Each test bundle contains: 25 test devices, 25 extraction tubes (prefilled with extraction decision 300 μL / tube), filtered nozzles, 1 tube stand, 25 sterile swabs and 1 bundle insert.
Provides required nonetheless couldn’t equipped: timer.
Specification
Examine Principle | Colloidal gold |
Sample Sort | Nasal swab, oropharyngeal swab or nasopharyngeal swab |
Sample Amount | 60 μL |
Examine Time | 15 min |
Operation Temperature | 15-30℃ |
Storage Temperature | 2-30℃ |
Shelf Life (Unopened) | 24 months |
SARS-CoV-2 Rapid Antigen Test Nasal |
|||
9901-NCOV-03G | Roche Diagnostics | 25 Tests/Kit | EUR 112.8 |
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) |
|||
IOV87952 | INVBIO | 20T/kit | EUR 46.8 |
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications. |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-2 | BPS Bioscience | 10 mg | EUR 3460 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag |
|||
E80027 | EpiGentek |
|
|
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial |
|||
E80028 | EpiGentek |
|
|
Spike (SARS-CoV-2) Lentivirus |
|||
78010-2 | BPS Bioscience | 500 µl x 2 | EUR 2095 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |
3CL Protease (SARS-CoV-2) |
|||
100823-2 | BPS Bioscience | 500 µg_x000D_ | EUR 3360 |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
Dynamiker Monkeypox Virus Ag Rapid Test |
|||
DNK-2114-1 | Dynamiker Biotechnology | 20 tests | EUR 702 |
Description: The product is a lateral flow chromatographic immunoassay for the qualitative detection of monkeypox virus antigen in human whole blood, serum, plasma or rash exuudate. The kit is intended for professional use only. |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
|||
E80024 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion |
|||
E80026 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag |
|||
E80021 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag |
|||
E80023 | EpiGentek |
|
|
PLPro, His-tag (SARS-CoV-2) |
|||
100735-2 | BPS Bioscience | 1 mg | EUR 3000 |
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa. |
NSP10/NSP16 Complex (SARS-CoV-2) |
|||
100747-2 | BPS Bioscience | 1 mg | EUR 2500 |
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system. |
NSP7, His-tag (SARS-CoV-2) |
|||
100829-2 | BPS Bioscience | 1 mg | EUR 2600 |
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa. |
NSP8, His-tag (SARS-CoV-2) |
|||
100830-2 | BPS Bioscience | 1 mg | EUR 2730 |
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa. |
Anti-Nucleocapsid Antibody (SARS-CoV-2 ) |
|||
100861-2 | BPS Bioscience | 100 µg | EUR 420 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein. |
ORF9b, GST-Tag (SARS-CoV-2) |
|||
100962-2 | BPS Bioscience | 1 mg | EUR 2720 |
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification. |
SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag |
|||
E80020 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag |
|||
E80022 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag |
|||
E80025 | EpiGentek |
|
|
3CL Protease (SARS-CoV-2) Assay Kit |
|||
79955-2 | BPS Bioscience | 384 rxns. | EUR 1265 |
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control. |
Spike S1, Fc fusion (SARS-CoV-2) |
|||
100688-2 | BPS Bioscience | 50 µg | EUR 505 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa. |
Anti-Spike S1 Antibody (SARS-CoV-2) |
|||
100715-2 | BPS Bioscience | 100 µg | EUR 440 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
Spike S2, Fc-Tag (SARS-CoV-2) |
|||
100895-2 | BPS Bioscience | 500 µg_x000D_ | EUR 1815 |
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa. |